---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-024338"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:50:48.149040+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Renalytix launches formal sale process after unsolicited approach from strategic diagnostic firm

## Summary
- Unsolicited approach from a large, publicly listed diagnostics company evaluating acquisition of all shares.
- Formal sale process launched; Stifel appointed as Sole Financial Adviser and Rule 3 Adviser.
- Advanced financing discussions with existing shareholders and potential new equity/debt providers underway.
- Cash on hand $2.3M plus $1.4M marketable securities as of March 3; expects cash to fund through April 2024.
- No certainty any offer will be made; Board may pursue alternative strategic options including staying independent.

## SEC filing metadata
- accession: 0000950170-24-024338
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017024024338/0000950170-24-024338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017024024338/rnlx-20240304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-024338
- JSON: https://secwatch.observer/filing/0000950170-24-024338.json
- Plain text: https://secwatch.observer/filing/0000950170-24-024338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.